Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer

Tony N. Talebi, Murugesan Manoharan, Rakesh Singal

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Patients with metastatic hormone-refractory prostate carcinoma may have dramatic and life-threatening coagulation complications from their disease. They are at risk for either clotting or bleeding events. We report the case of a man with metastatic castration-resistant prostate cancer with disseminated intravascular coagulation who had both clotting and bleeding in addition to thrombocytopenia. The patient did not respond to supportive therapy and was treated with docetaxel despite a platelet count of 46/mm. The treatment resulted in resolution of disseminated intravascular coagulation, normalization of the platelet count, and resolution of hematuria. We review disseminated intravascular coagulation in prostate cancer and different possible treatments.

Original languageEnglish (US)
Pages (from-to)e59-e61
JournalAmerican journal of therapeutics
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • disseminated intravascular coagulation
  • docetaxel
  • hematuria
  • prostate cancer
  • thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer'. Together they form a unique fingerprint.

  • Cite this